Sign Out
Pharmacology: Pharmacodynamics: Levodropropizine is one of the therapeutic options used to treat acute and chronic bronchitis. Levodropropizine is a peripherally acting, non-opioids antitussive agent, which inhibits the cough reflex by reducing the release of sensory peptide in the peripheral region and suppresses the afferent pathway of pulmonary.
Pharmacokinetics: Levodropropizine is rapidly absorbed into the gastrointestinal tract, with time required to reach the maximum drug concentration (Tmax) ranging from 0.25 to 0.75 h. This absorption profile is due to high bioavailability (>75%) and rapid distribution of levodropropizine. The mean terminal half-life (t½) of levodropropizine is 2.73 h, which suggests rapid elimination after systemic absorption. Levodropropizine has linear pharmacokinetic (PK) characteristics at doses ranging from 30 to 90 mg.
